Hypoglycemia Induces Tau Hyperphosphorylation

Abstract

Cerebral hypoglycemia/hypometabolism is associated with Alzheimer's disease (AD) and is routinely used to assist clinical diagnosis of AD by brain imaging. However, whether cerebral hypoglycemia/hypometabolism contributes to the development of AD or is a response of reduced neuronal activity remains unclear. To investigate the causal relationship, we cultured the differentiated N2a neuroblastoma cells in glucose/pyruvate-deficient media (GDM). Shortly after the N2a cells cultured in the GDM, the mitochondria membrane potential was reduced and the AMP-activated-proteinkinase (AMPK), an energy sensor, was activated. Treatment of GDM not only increased the levels of tau phosphorylation at Ser(262) and Ser(396), but also increased the levels of active forms of GSK3α and GSK3β, two known kinases for tau phosphorylation, of the N2a cells. The levels of activated Akt, a mediator downstream to AMPK and upstream to GSK3α/β, were reduced by the GDM treatment. The effect of hypoglycemia was further examined in vivo by intracerebroventricular (icv) injection of streptozotocin (STZ) to the Wistar rats. STZ selectively injuries glucose transporter type 2-bearing cells which are primarily astrocytes in the rat brain, hence, interrupts glucose transportation from blood vessel to neuron. STZicv injection induced energy crisis in the brain regions surrounding the ventricles, as indicated by higher pAMPK levels in the hippocampus, but not cortex far away from the ventricles. STZ-icv treatment increased the levels of phosphorylated tau and activated GSK3β, but decreased the levels of activated Akt in the hippocampus. The hippocampus-dependent spatial learning and memory was impaired by the STZ-icv treatment. In conclusion, our works suggest that hypoglycemia enhances the AMPK-Akt-GSK3 pathway and leads to tau hyperphosphorylation.

Evidence of neurodegeneration in obstructive sleep apnea: Relationship between obstructive sleep apnea and cognitive dysfunction in the elderly

“…A decrease in glucose metabolism in the hypoxic and hypoperfused brain may trigger the process of neuronal degeneration in AD. Hypoglycemia increases neuronal tau hyperphosphorylation (Lee et al, ). Intracerebroventricular injection of streptozotocin (STZ) in Wistar rats selectively affected glucose transporter type 2‐bearing cells (astrocytes) and interrupted glucose supply to neurons.…”

LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy

“…LX2343 ameliorated learning and memory impairments in ICV-STZ rats ICV injection of rats with a sub-diabetogenic dose of STV has been shown to be closely linked to the sporadic dementia of Alzheimer's disease [34] , which is characterized by cognitive impairment [35] , OS [35] , impaired glucose metabolism [36] , and hyperphosphorylated tau [37] . Given the pathological features of ICV-STZ rats and the efficiency of LX2343 in both protecting neuronal cells and attenuating tau pathology, we performed the MWM assay to examine the potential of LX2343 in the amelioration of memory impairment in ICV-STZ rats.…”

Early Alzheimer’s and Parkinson’s Disease Pathology in Urban Children: Friend versus Foe Responses—It Is Time to Face the Evidence

“…There are very few arguments about the role of abnormal tau hyperphosphorylation in AD, related tauopathies and under experimental conditions [108, 109, 114–118]. A subject to be explored in air pollution animal models ought to be the characterization of the HP τ and if indeed represents a compensatory neuronal response against oxidative stress.…”